myocard
defin
subclin
inflamm
heart
muscl
may
induc
infecti
toxic
immunolog
agent
among
differ
infecti
pathogen
virus
common
caus
myocard
serolog
studi
nucleicacid
hybrid
pcrbase
studi
endomyocardi
biopsi
autopsi
specimen
shown
enterovirus
repres
one
common
group
virus
detect
myocardium
although
myocard
frequent
diseas
often
goe
unrecogn
base
randomli
select
routin
autopsi
perform
year
period
popul
found
lymphocyt
myocard
case
myocard
detect
group
young
adult
age
coxsackievirus
belong
famili
picornavirida
genu
enteroviru
virus
positivestrand
rna
genom
kb
encod
monocistron
polyprotein
process
matur
peptid
translat
viral
proteas
four
capsid
protein
seven
nonstructur
protein
found
coxsackieviru
infect
cell
base
differ
organ
tropism
differ
organ
damag
observ
mice
coxsackievirus
classifi
two
group
group
coxsackievirus
cva
member
wherea
group
b
coxsackievirus
cvb
six
member
coxsackievirus
commonli
induc
mild
diseas
circumst
seem
depend
genet
individu
predisposit
virus
overcom
local
host
defens
induc
sever
infect
heart
pancrea
brain
cvb
group
includ
serotyp
particular
frequent
associ
infect
heart
cours
heart
infect
patient
may
differ
typic
induc
acut
myocardi
infect
case
patient
undergo
complet
recoveri
fulmin
infect
howev
occur
result
sudden
death
viru
elimin
host
immun
defens
mechan
persist
infect
dilat
cardiomyopathi
dcm
one
lead
caus
heart
transplant
develop
incid
enterovir
infect
heart
patient
myocard
dcm
variabl
infect
rate
observ
although
dcm
multipl
caus
evid
dcm
patient
infect
enterovirus
pathogen
mechan
induc
myocard
yet
fulli
understood
enterovirus
play
activ
role
develop
myocard
human
especi
fulmin
acut
cours
infect
support
detect
enterovir
replic
intermedi
minusstrand
enterovir
rna
patient
left
ventricular
dysfunct
suspect
clinic
myocard
contrast
patient
idiopath
dcm
chronic
coronari
diseas
ccd
repres
endstag
cardiac
diseas
patient
posit
enteroviru
genom
small
percentag
activ
enterovir
replic
myocardium
moreov
fulli
replic
viru
could
isol
myocardium
patient
chronic
heart
infect
coxsackievirus
persist
latent
form
anim
model
shown
viru
persist
result
product
stabl
doublestrand
rna
associ
delet
nontransl
region
viral
genom
base
observ
import
determin
whether
replic
defici
coxsackieviru
variant
abl
induc
dcm
prove
wess
et
al
gener
transgen
mice
express
replic
restrict
cdna
exclus
heart
anim
express
coxsackievir
genom
cardiomyocyt
lowlevel
without
form
infecti
viru
particl
histopatholog
analysi
transgen
heart
reveal
typic
morpholog
featur
myocardi
interstiti
fibrosi
degener
myocyt
resembl
dcm
human
function
chang
accompani
decreas
systol
function
excitationcontract
coupl
abnorm
similar
pressur
overload
model
dcm
thu
studi
confirm
nonrepl
coxsackievirus
suffici
induc
dcm
studi
vitro
vivo
model
carri
last
year
contribut
significantli
elucid
import
aspect
molecular
pathogen
mechan
cardiac
coxsackieviru
infect
base
studi
clear
direct
viru
induc
injuri
well
immun
autoimmun
mechan
trigger
viral
infect
involv
develop
coxsackieviru
induc
myocard
impact
direct
viru
induc
cytotox
support
fact
rna
detect
stage
heart
infect
viru
replic
correl
neg
clinic
outcom
suggest
continu
replic
viru
involv
progress
diseas
furthermor
shown
enteroviru
induc
cytotox
directli
relat
express
viral
protein
express
two
viral
proteas
induc
apoptosi
activ
extrins
pathway
intrins
mitochondriamedi
apoptosi
pathway
proteas
also
cleav
eukaryot
translat
initi
factor
eif
lead
cessat
host
protein
synthesi
abl
cleav
dystrophin
infect
cultur
myocyt
infect
mous
heart
latter
thought
play
role
releas
viru
myocyt
sinc
viral
infect
increas
absenc
dystrophin
importantli
impair
dystrophin
function
lead
disrupt
extrasarcomer
cytoskeleton
loss
transmiss
mechan
forc
extracellular
matrix
seem
import
factor
contribut
develop
dcm
although
therapeut
approach
aim
modul
inhibit
immun
system
immunoglobulin
therapi
immunoabsopt
specif
antibodi
therapi
hold
also
promis
treatment
myocardi
enterovir
infect
review
focu
direct
pharmacolog
biolog
therapi
target
specif
point
viru
replic
cycl
inhibit
coxsackievirusinduc
myocard
first
essenti
step
viral
infect
interact
viral
capsid
receptor
surfac
host
cell
coxsackieviru
capsid
assembl
ident
protom
compos
four
structur
protein
viral
shell
form
lie
inner
surfac
establish
connect
capsid
rna
genom
surfac
virion
show
fivefold
axi
symmetri
surround
larg
depress
term
canyon
contain
hydrophob
pocket
coxsackieviru
adenoviru
receptor
car
primari
receptor
cvb
bind
pocket
canyon
floor
cvb
mediat
intern
viru
host
cell
sever
drug
develop
select
inhibit
interact
cvb
car
win
compound
antivir
drug
interact
hydrophob
pocket
bottom
canyon
figur
discov
initi
sterlingwinthrop
research
institut
first
use
inhibit
rhinoviru
infect
small
molecul
inhibit
interact
virion
cellular
receptor
molecul
thu
prevent
viru
bind
target
cell
receptor
furthermor
bind
specif
win
molecul
pocket
result
increas
protein
rigid
stabil
entir
viral
capsid
enzymat
degrad
uncoat
releas
viral
rna
cytoplasm
prevent
last
year
mani
win
base
drug
test
regard
inhibitori
effect
differ
member
picornaviru
famili
rhinoviru
polioviru
echoviru
enteroviru
win
broadspectrum
antipicornavir
drug
one
first
win
compound
clinic
test
effect
human
rhinoviru
echoviru
also
enteroviru
infect
shown
vitro
vivo
vitro
studi
demonstr
win
reduc
picornaviru
titer
order
magnitud
vivo
administr
mice
experiment
infect
led
reduct
proport
cardiomyocyt
contain
viral
rna
significantli
inhibit
cardiomyocyt
apoptosi
moreov
administr
drug
result
complet
protect
mortal
infect
mice
latter
studi
reveal
strong
decreas
viru
induc
mortal
occur
treatment
start
concomit
infect
onset
therapi
delay
one
day
surviv
observ
wherea
nontreat
group
anim
surviv
demonstr
signific
longer
complet
protect
viru
therapeut
effect
still
notabl
treatment
initi
day
viru
inocul
thu
win
therapi
almost
fulli
effect
within
hour
infect
benefici
effect
declin
time
win
treatment
howev
abrog
inflammatori
reaction
myocardium
infect
anim
shown
phase
clinic
trial
rhinoviru
infect
myocard
model
mice
infect
coxsackieviru
low
dose
win
well
toler
higher
dose
mgkgday
howev
neurolog
toxic
observ
murin
myocard
model
vivo
moreov
compound
rapidli
metabol
induc
revers
hepat
made
compound
uninterest
studi
end
win
pleconaril
repres
novel
oral
avail
systemicallyact
compound
win
seri
high
oral
bioavail
long
plasma
halflif
compound
broad
spectrum
antivir
activ
clinic
isol
prototyp
strain
enterovirus
includ
vitro
pleconaril
extens
evalu
clinic
studi
antipicornaviru
drug
show
clear
efficaci
treatment
variou
picornavirusassoci
ill
wherea
side
effect
rare
one
studi
rotbart
et
al
investig
therapeut
respons
pleconaril
treatment
follow
studi
patient
potenti
lifethreaten
enteroviru
infect
patient
clinic
respons
tempor
associ
pleconaril
therapi
similar
degre
patient
show
virolog
laboratori
radiolog
respons
clinic
trial
howev
reveal
therapeut
efficaci
pleconaril
depend
viru
speci
target
signific
therapeut
effect
appar
treatment
rhinoviru
sever
enteroviru
infect
feder
drug
administr
fda
usa
declin
approv
pleconaril
treatment
common
cold
panel
remain
unconvinc
drug
safeti
profil
pleconaril
yet
use
clinic
trial
explicitli
treatment
enteroviru
induc
myocard
vivo
studi
carri
pevear
et
al
howev
demonstr
effici
antivir
efficaci
compound
enteroviru
induc
mous
myocard
mice
show
reduc
mortal
reduct
titer
heart
order
magnitud
sever
studi
demonstr
natur
occur
mutant
resist
pleconaril
moreov
pleconaril
treatment
seem
result
rapid
emerg
resist
mutant
mutant
predominantli
contain
singl
amino
acid
substitut
leumet
hydrophob
pocket
canyon
prevent
effici
bind
compound
impair
bind
viru
cellular
receptor
order
overcom
viru
resist
new
pleconaril
deriv
recent
synthes
success
test
pleconarilresist
mutant
last
year
sever
addit
new
drug
develop
function
similar
win
compound
good
antivir
efficaci
rhinoviru
infect
less
activ
coxsackieviru
infect
thu
search
potent
highli
bioavail
compound
broad
antivir
spectrum
high
efficaci
goe
second
class
picornaviru
inhibitor
compris
drug
interfer
viral
protein
replic
compound
interact
nonstructur
protein
viral
proteas
rnadepend
rna
polymeras
therebi
inhibit
viral
replic
infect
cell
seri
compound
guanidin
hypochlorid
hbb
interact
viral
protein
result
inhibit
viral
rna
synthesi
lead
protect
cell
virusinduc
cell
lysi
figur
antivir
activ
coxsackievirus
investig
vitro
experi
experi
howev
reveal
singl
mutat
viral
protein
suffici
confer
resist
antivir
treatment
nitric
oxid
donor
form
anoth
class
molecul
interfer
function
viral
nonstructur
protein
figur
inhibit
enteroviru
proteas
snitrosyl
proteas
involv
host
cell
shutoff
lead
develop
cytopath
effect
donor
gtn
isdn
abl
inhibit
coxsackieviru
proteas
induc
signific
antivir
effect
vitro
furthermor
gtn
significantli
reduc
sign
myocard
administr
decreas
immun
cell
infiltr
virusinduc
fibrosi
day
postinfect
pi
anoth
studi
nodonor
nometoprolol
novel
noreleas
deriv
adrenerg
receptor
agonist
metoprolol
shown
metoprolol
improv
surviv
remodel
fibrosi
left
ventricular
systol
function
knockin
mous
model
inherit
dilat
cardiomyopathi
myocard
mous
model
treatment
nometoprolol
display
enhanc
therapeut
benefit
compar
metoprolol
signific
reduct
viral
rna
copi
number
bodi
weight
loss
infiltr
fibrosi
score
sever
nucleosid
analogu
analyz
respect
antipicornavir
potenc
intens
studi
drug
ribavirin
synthet
nucleosid
structur
relat
inosin
guanosin
ribavirin
incorpor
viral
rna
induc
mutat
lethal
viru
figur
shown
ribavirin
broad
antivir
activ
sever
rna
virus
vivo
eg
rsv
measl
lassa
hepat
c
virus
vitro
activ
ribavirin
enterovirus
demonstr
sever
group
treatment
murin
myocard
led
significantli
decreas
myocardi
viru
titer
inflamm
necrosi
myocardi
calcif
one
side
effect
ribavirin
treatment
howev
hemolyt
anemia
ribavirin
may
contraind
patient
acut
chronic
myocard
studi
harki
et
al
synthes
cytidin
analogu
evalu
antivir
activ
one
test
molecul
decreas
viral
titer
infect
cell
higher
effici
ribavirin
far
result
vivo
studi
report
third
group
antivir
drug
includ
molecul
interact
cellular
protein
therebi
interfer
viral
replic
sever
studi
shown
ubiquitin
requir
effect
replic
differ
virus
among
coxsackieviru
ubiquitinproteasom
system
up
major
intracellular
pathway
protein
degrad
cellular
protein
recycl
pathway
up
thu
play
key
role
regul
varieti
fundament
cellular
process
signal
transduct
cell
cycl
regul
apoptosi
antigen
process
transcript
regul
dna
repair
last
year
sever
inhibitori
substanc
target
up
analyz
abil
inhibit
coxsackieviru
infect
figur
pyrrolidin
dithiocarbam
pdtc
curcumin
natur
polyphenol
compound
extract
curcuma
longa
reduc
coxsackievir
rna
synthesi
protein
express
progeni
releas
respect
vitro
upsinhibitor
peptidealdehyd
lactacystin
reduc
infect
murin
cardiomyocyt
cell
line
increas
cell
viabil
treatment
infect
mice
proteasom
inhibitor
howev
result
slight
decreas
viralinduc
mortal
myocardi
injuri
signific
inhibit
viral
replic
heart
detect
although
up
inhibitor
may
potenti
therapeut
tool
treatment
coxsackieviru
infect
rel
low
effici
possibl
druginduc
side
effect
may
limit
use
treatment
coxsackieviru
infect
human
summari
last
year
mani
pharmacolog
activ
low
molecular
weight
substanc
develop
concomit
improv
knowledg
picornaviru
structur
replic
cycl
advers
properti
bioavail
safeti
drug
rapid
develop
escap
mutant
part
low
efficaci
current
limit
use
treatment
myocardi
coxsackievir
infect
human
interferon
ifn
belong
group
cytokin
antivir
immunomodul
activ
suspect
earli
investig
demonstr
releas
cytokin
infect
human
monocyt
role
ifn
infect
becam
obviou
knockout
mice
prove
highli
suscept
infect
develop
breakdown
disrupt
cardiomyocyt
vivo
vitro
studi
demonstr
antivir
efficaci
ifn
treatment
coxsackieviru
infect
heart
heim
et
al
show
antivir
activ
recombin
ribavirin
natur
human
cotreat
carrier
state
infect
cultur
human
myocardi
fibroblast
vitro
anoth
studi
wang
et
al
confirm
antivir
cardioprotect
efficaci
murin
induc
mice
myocard
model
vivo
potenc
ifn
treatment
myocardi
enterovir
infect
human
demonstr
sever
year
ago
twentytwo
patient
entero
adenovir
myocardi
persist
treat
period
six
month
enterovir
genom
elimin
patient
viral
clearanc
parallel
signific
decreas
left
ventricular
end
diastol
end
systol
diamet
heart
improv
left
ventricular
function
moreov
well
toler
studi
patient
show
flulik
side
effect
first
week
treatment
could
effici
suppress
nonsteroid
antiinflammatori
drug
investig
therapeut
potenti
current
carri
ongo
multicent
random
bayer
schere
pharma
ag
studi
patient
chronic
viral
cardiomyopathi
bicc
studi
antisens
approach
proven
promis
strategi
inhibit
virus
convent
antisens
oligonucleotid
singlestrand
molecul
compos
dna
monom
modifi
variant
thereof
antisens
oligonucleotid
bind
complementari
viru
rna
prevent
translat
induc
degrad
rnase
h
antisens
oligonucleotid
approv
regulatori
author
date
fomivirsen
phosphorothioatemodifi
dna
oligonucleotid
use
treat
retin
induc
cytomegaloviru
discontinu
sinc
drug
market
shrank
antisens
oligonucleotid
also
consid
novel
tool
inhibit
initi
screen
seven
antisens
oligonucleotid
design
target
utr
evalu
respect
antivir
activ
hela
cell
phosphorothioatemodifi
oligodeoxynucleotid
use
resist
degrad
cellular
nucleas
effici
viru
inhibit
achiev
antisens
oligonucleotid
direct
either
two
untransl
region
effici
antisens
molecul
target
utr
subsequ
use
inhibit
cell
vivo
antisens
oligonucleotid
strongli
inhibit
viral
rna
protein
synthesi
cell
cultur
intraven
administr
aj
mice
decreas
viral
titer
improv
vivo
deliveri
cellpenetr
argininerich
peptid
conjug
morpholino
oligom
sinc
morpholino
oligom
induc
rnase
h
cleavag
target
rna
mechan
action
base
steric
blockad
target
rna
function
intraven
administr
oligom
prior
infect
result
enhanc
approxim
order
magnitud
decreas
viral
titer
significantli
less
damag
cardiac
tissu
highli
effici
natur
rnai
come
surpris
rnai
evalu
novel
strategi
inhibit
initi
studi
show
sirna
code
region
viru
genom
reveal
signific
antivir
activ
untransl
region
order
investig
mechan
rnaimedi
inhibit
detail
sirna
intent
design
target
either
viral
plu
strand
minu
strand
studi
provid
clear
evid
silenc
viral
plusstrand
key
inhibit
like
minusstrand
might
inaccess
silenc
machineri
major
problem
long
term
inhibit
virus
emerg
escap
mutant
limit
well
known
convent
antivir
therapi
lowmolecular
weight
drug
applic
rnai
approach
well
viru
escap
consequ
accumul
point
mutat
close
sirna
target
site
observ
variou
type
virus
includ
polioviru
hiv
three
counterstrategi
follow
counter
problem
viral
escap
target
conserv
region
viru
genom
combin
effici
antivir
sirna
silenc
host
factor
essenti
viral
life
cycl
mutat
highli
conserv
region
viru
genom
like
caus
loss
virul
comparison
silenc
sirna
differ
genom
region
reveal
target
nonstructur
protein
code
region
superior
select
structur
protein
code
region
sinc
enzym
often
lose
activ
mutat
occur
sever
group
initi
direct
sirna
untransl
region
utr
genom
harbor
intern
ribosom
entri
site
ire
interestingli
none
test
sirna
exert
signific
antivir
activ
possibl
explan
unexpect
find
tight
structur
ire
detriment
sirnamedi
gene
silenc
labori
screen
access
site
complementari
oligonucleotid
utr
could
sirna
target
ire
develop
capabl
inhibit
antivir
activ
sirna
improv
partial
modif
lock
nucleic
acid
lna
high
affin
toward
complementari
rna
anoth
highli
conserv
region
genom
cisact
replic
element
cre
locat
protein
code
region
sirna
direct
region
confer
sustain
protect
prevent
emerg
viabl
escap
mutant
sinc
cre
sequenc
ident
enterovirus
echovirus
atyp
well
btype
coxsackievirus
sirna
univers
persist
antienterovir
activ
wide
employ
strategi
minim
viral
escap
convent
viru
therapi
combin
variou
agent
antivir
activ
hiv
approach
known
highli
activ
antiretrovir
therapi
haart
combin
antiretrovir
therapi
adapt
idea
rnai
combin
two
activ
sirna
shrna
combin
two
shrna
express
cassett
one
vector
found
maintain
silenc
activ
mutat
target
rna
report
system
sinc
second
shrna
compens
loss
silenc
activ
shrna
direct
mutat
target
site
systemat
investig
viral
escap
cell
cultur
reveal
cocktail
three
sirna
target
distinct
site
viru
genom
could
maintain
therapeut
efficaci
viru
inhibit
dual
singlemoleculebas
rnai
abrog
viral
escap
long
run
howev
resist
mutant
like
develop
even
combin
three
sitespecif
sirna
therefor
recent
idea
advanc
use
pool
sirna
cover
kb
genom
sequenc
pool
gener
synthes
long
doublestrand
rna
cover
region
encod
nonstructur
protein
subsequ
cleav
sirna
recombin
dicer
pool
found
significantli
effect
singlesit
sirna
although
strategi
expect
prevent
viral
escap
therapeut
applic
question
sinc
antivir
agent
consist
heterogen
mixtur
hundr
differ
sirna
molecul
current
unclear
whether
pool
sirna
induc
sever
offtarget
effect
singl
sirna
sinc
consist
numer
sequenc
potenti
regul
nontarget
rna
third
strategi
sustain
inhibit
viral
spread
silenc
gene
host
cell
requir
viru
enter
cell
replic
figur
advantag
approach
virus
limit
capac
adapt
host
cell
chang
initi
attach
decayacceler
factor
daf
serv
coreceptor
prior
viru
enter
host
cell
via
car
wherea
car
essenti
cardiac
infect
well
strain
bind
daf
expect
silenc
car
found
prevent
infect
treat
cell
whether
car
consid
therapeut
target
debat
sinc
essenti
prerequisit
medic
applic
strategi
would
factor
dispens
car
locat
tight
junction
epitheli
cell
constitut
knockout
found
result
embryon
lethal
condit
associ
cardiac
defect
contrast
anim
condit
knockout
car
later
time
point
embryon
develop
surviv
adulthood
evid
cardiac
abnorm
detail
investig
heart
function
howev
reveal
block
atrioventricular
conduct
develop
absenc
car
adult
mous
heart
may
lead
arrhythmia
find
confirm
recent
condit
knockout
mice
exhibit
complet
atrioventricular
block
variou
phenotyp
organ
well
howev
note
direct
conclus
drawn
knockout
experi
rnai
applic
sinc
knockout
anim
complet
lack
car
rnai
result
partial
knockdown
target
gene
express
possibl
leav
enough
prevent
defect
occur
sinc
car
might
essenti
cellular
function
host
factor
consid
target
inhibitor
block
indirectli
recent
studi
rnai
screen
cover
druggabl
genom
carri
identifi
cellular
factor
requir
infect
human
cell
approach
set
gene
could
identifi
whose
deplet
inhibit
infect
studi
necessari
evalu
whether
gene
suitabl
candid
develop
inhibitor
antivir
activ
cellular
deliveri
potenc
specif
sirna
improv
chemic
modif
doublestrand
rna
addit
lnamodifi
sirna
mention
sirna
contain
lna
well
unlock
nucleic
acid
una
test
studi
design
pattern
could
elucid
una
monom
compromis
high
antivir
sirna
activ
studi
shown
introduct
una
sirna
minim
offtarget
activ
constitut
one
major
challeng
associ
clinic
use
rnai
second
major
hurdl
applic
rnai
effici
cellular
deliveri
sirna
attach
lipophil
molecul
cholesterol
receptor
ligand
like
folat
shown
improv
case
celltyp
specif
cellular
uptak
given
sirna
even
absenc
deliveri
agent
folatelink
bacteri
phage
packag
rna
use
vehicl
deliv
doublestrand
rna
hela
cell
folat
receptor
posit
cancer
cell
line
wide
use
vitro
model
infect
develop
strategi
artifici
micro
rna
amirna
target
untransl
region
genom
instead
standard
sirna
use
silenc
mediat
amirna
design
contain
mismatch
central
region
target
site
shown
toler
mutat
thu
potenti
suppress
viral
escap
mutant
major
challeng
develop
new
therapeut
strategi
translat
knowledg
gain
cell
cultur
experi
vivo
situat
sirna
target
proteas
encod
genom
region
found
lead
signific
reduct
viral
tissu
titer
attenu
tissu
damag
prolong
surviv
highli
suscept
type
interferon
receptorknockout
mice
outlin
prolong
silenc
achiev
continu
intracellular
gener
shrna
express
cassett
proofofprincipl
approach
plasmidderiv
shrna
use
inhibit
balbc
mice
two
test
shrna
exert
strong
antivir
effect
accompani
attenu
pancreat
tissu
damag
aforement
studi
howev
sirna
shrna
express
plasmid
respect
appli
hydrodynam
transfect
method
involv
high
pressur
inject
nucleic
acid
tail
vein
lend
therapeut
set
human
therefor
necessari
develop
altern
applic
rout
effici
rnaimedi
inhibit
sinc
deliveri
chemic
synthes
sirna
across
endotheli
barrier
cardiomyocyt
ineffici
even
presenc
transfect
agent
transfer
shrna
express
cassett
viral
vector
appear
method
choic
kim
et
al
use
lentivir
vector
deliv
express
cassett
mention
shrna
highli
conserv
cre
region
mice
inject
intraperiton
lentivir
vector
subsequ
challeng
treat
anim
signific
reduct
viral
titer
viral
myocard
proinflammatori
cytokin
importantli
surviv
rate
improv
day
ten
infect
sinc
retrovir
vector
bear
risk
insert
mutagenesi
adenovir
vector
induc
strong
immun
respons
vector
base
adenoassoci
virus
aav
consid
promis
vehicl
gene
transfer
wild
type
viru
singlestrand
recent
use
viral
vector
contain
selfcomplementari
doubl
strand
genom
ensur
rapid
onset
high
level
express
transgen
furthermor
tissu
tropism
viral
vector
direct
use
pseudotyp
aav
vector
consist
genom
base
standard
serotyp
capsid
protein
differ
serotyp
could
show
deliveri
shrna
doubl
express
cassett
pseudotyp
selfcomplementari
aav
vector
primari
rat
cardiomyocyt
inhibit
replic
order
magnitud
moreov
mice
myocard
rnai
treatment
significantli
attenu
cardiac
dysfunct
taken
togeth
vitro
studi
demonstr
rnai
effici
approach
inhibit
subsequ
vivo
studi
confirm
viral
vector
suitabl
vehicl
deliveri
shrna
express
cassett
heart
technolog
thu
potenti
develop
therapeut
option
treat
human
virusinduc
myocard
prerequisit
success
viru
uptak
specif
bind
viru
cellular
receptor
solubl
receptor
analogu
sra
bind
viru
viru
interact
cellular
receptor
thu
prevent
bind
viru
subsequ
uptak
target
cell
sra
found
natur
occur
cellular
protein
gener
altern
splice
cellular
receptor
transcript
artifici
design
recombin
protein
genet
engin
mani
sra
lack
transmembran
domain
domain
necessari
anchor
natur
receptor
protein
cell
membran
absenc
enabl
sra
pass
cell
membran
accumul
extracellular
space
gener
sra
exclus
consist
viru
bind
site
suffici
neutral
target
viru
effici
howev
sometim
poor
allow
use
therapeut
treatment
genet
engin
increas
sra
effici
common
modif
repres
fusion
viru
bind
domain
carboxyterminu
human
fc
region
result
gener
dimer
antibodylik
molecul
import
effect
result
modif
antibodi
fcregion
promot
solubil
sra
halflif
fusion
protein
increas
vivo
recognit
iggfc
domain
fc
receptor
express
surfac
macrophag
enabl
clear
viru
shortli
viru
bound
solubl
receptor
peptid
phagocyt
cell
moreov
larg
amount
solubl
iggfc
easili
purifi
use
protein
acoupl
sepharos
context
shown
neutral
effici
solubl
dafigg
fc
fusion
protein
sdaffc
monomer
sdaf
homologu
compris
cellular
daf
ectodomain
altern
viru
bind
domain
viru
receptor
fuse
ctermin
part
bind
protein
chain
lead
product
disulfidelink
homooctam
solubl
protein
spiderlik
structur
christiansen
et
al
report
fusion
protein
encompass
ectodomain
link
ctermin
part
chain
abl
bind
measl
viru
hemagglutinin
protein
express
murin
cell
higher
avid
solubl
monomer
moreov
fulli
protect
transgen
mice
lethal
intracrani
measl
viru
challeng
competit
inhibit
well
steric
problem
entri
uncoat
step
seem
main
mechan
respons
block
virus
sra
anoth
signific
block
mechan
elucid
sra
target
virus
picornaviru
famili
analog
physiolog
mechan
occur
natur
viru
bind
cell
receptor
shown
exposur
coxsackievirus
viru
specif
sra
induc
format
alter
particl
figur
aparticl
low
buoyant
densiti
lack
viral
rnagenom
particl
lost
capac
infect
cell
format
irrevers
process
protect
effect
sra
describ
sever
virus
includ
hiv
adenoviru
measl
viru
human
herpesviru
effect
also
demonstr
sever
member
picornovirida
includ
entereroviru
rhinoviru
poliovirus
test
potenti
inhibit
coxsackieviru
myocard
sra
car
scarfc
daf
sdaffc
develop
analyz
differ
myocard
model
yanagawa
et
al
inject
recombin
sdaffc
mice
day
concurr
day
infect
histolog
examin
demonstr
signific
reduct
lesion
area
cell
necrosi
calcif
inflamm
heart
anim
treat
concurr
postinfect
group
howev
group
similar
reduct
infecti
heart
similar
result
subsequ
obtain
scarfc
therapeut
effect
induc
scarfc
howev
seem
stronger
observ
sdaffc
especi
pre
concomit
treat
group
moreov
scarfc
inhibit
induc
pancreat
vivo
found
sdaffc
differ
effici
explain
fact
scarfc
bind
affin
equival
form
daf
also
fact
scarfc
induc
aparticl
wherea
sdaffc
form
revers
complex
may
contribut
observ
figur
although
result
convincingli
demonstr
sdaffc
scarfc
effici
inhibit
myocard
comprehens
assess
regard
impact
contractil
heart
paramet
import
paramet
clinic
perspect
carri
studi
therefor
aim
character
protect
effect
scarfc
treatment
detail
end
clone
scarfc
insert
adenovir
vector
control
doxycyclin
dox
induc
promot
follow
system
applic
scarfc
express
induc
addit
dox
day
concomit
day
infect
induct
scarfc
prior
infect
complet
block
viru
even
concomit
postinfect
induct
strongli
reduc
cardiac
infect
myocardi
injuri
inflamm
moreov
signific
improv
systol
diastol
cardiac
paramet
detect
anim
scarfc
express
induc
prior
concomit
infect
dox
induct
result
therapeut
serum
level
scarfc
rang
ngml
hour
induct
earliest
improv
hemodynam
paramet
concomit
group
reveal
scarfc
distinct
therapeut
effect
heart
function
approach
aim
gener
scarfcsdaffc
variant
increas
effici
lim
et
al
construct
scarsdaf
receptor
chimera
contain
viru
bind
site
hcar
hdaf
fuse
human
fc
region
one
fusion
protein
hcar
hdaffc
show
stronger
neutral
activ
scarfc
vitro
employ
vivo
result
significantli
higher
surviv
rate
infect
mice
observ
scarfc
final
one
studi
analyz
potenti
natur
occur
scar
variant
origin
detect
car
splice
variant
hela
cell
inhibit
myocard
although
viral
load
heart
infect
anim
treat
significantli
reduc
surprisingli
anim
develop
sign
autoimmun
myocard
character
aggrav
myocardi
inflamm
tissu
damag
presenc
carspecif
antibodi
autoreact
myocardi
tissu
mechan
lead
autoimmunolog
side
effect
induc
yet
understood
may
specif
immunolog
reaction
relat
specif
sequenc
perhap
relat
fact
recombin
produc
bacteria
alter
glycosyl
pattern
increas
risk
copurifi
proinflammatori
substanc
regard
note
approach
employ
scar
sdaf
variant
infect
mice
vivo
lead
side
effect
mention
demonstr
gener
featur
scar
sdaf
therapeut
potenti
combin
scarfc
sdaffc
therapeut
approach
pharmacolog
activ
low
molecular
weight
substanc
rnai
immunomodul
myocard
remain
uncov
one
initi
exampl
recent
demonstr
simultan
applic
scarfc
sirna
exert
synergist
antivir
activ
treatment
persist
infect
cardiac
cell
line
vitro
studi
current
underway
verifi
result
myocard
model
vivo
summar
data
conclud
scarfc
sdaffc
repres
novel
promis
biolog
may
potenti
use
treatment
coxsackieviru
infect
human
howev
sever
question
still
unansw
must
address
research
coxsackievirus
develop
resist
scar
sdaf
safeti
profil
long
term
applic
scar
sdaf
inhibit
develop
chronic
form
myocard
due
great
progress
made
understand
stem
cell
therapi
recent
year
applic
stem
cell
consid
one
promis
strategi
therapeut
intervent
futur
regen
approach
aim
restor
physiolog
cellular
composit
diseas
organ
recent
research
indic
mammalian
heart
repopul
cell
extracardiac
sourc
transplant
exogen
cell
therefor
consid
like
next
gener
cardiac
cell
therapi
mesenchym
stem
cell
msc
particular
advantag
nonimmunogen
thu
allow
use
allogen
msc
clinic
applic
recent
preclin
studi
potenti
msc
improv
myocard
induc
demonstr
first
time
prerequisit
clinic
applic
strategi
msc
shown
infect
like
due
low
express
level
car
cocultur
experi
cardiomyocyt
cell
line
msc
reduc
apoptosi
oxid
stress
furthermor
msc
diminish
viral
progeni
releas
approxim
importantli
intraven
inject
msc
decreas
cardiac
apoptosi
improv
left
ventricular
function
experiment
model
murin
acut
myocard
detail
mechanist
analysi
reveal
protect
effect
msc
mediat
nodepend
manner
requir
prime
via
research
howev
requir
investig
possibl
side
effect
potenti
msc
transplant
treatment
induc
myocard
coxsackievirus
one
import
infecti
agent
associ
acut
chronic
myocard
human
base
elucid
coxsackievir
replic
cycl
wide
panel
pharmacolog
activ
low
molecular
weight
substanc
strong
antivir
activ
develop
date
none
routin
clinic
use
recent
biolog
sra
sirna
msc
found
suitabl
inhibit
viral
replic
inhibit
coxsackieviru
myocard
tabl
investig
necessari
elucid
full
therapeut
potenti
safeti
profil
base
understand
pathogenesi
coxsackievirusinduc
myocard
consid
viral
immun
autoimmun
mechan
involv
progress
diseas
antivir
therapi
combin
immunomodulatori
therapi
may
hold
greatest
potenti
improv
therapeut
outcom
coxsackieviru
infect
